At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 07:30 ET
Cytokinetics presented new aficamten data at HCMS/AHA 2026, including positive cardiac remodeling and patient-reported outcomes from the ACACIA-HCM nHCM trial and long-term safety from FOREST-HCM. The data support the upcoming sNDA filing for aficamten in non-obstructive HCM, but no regulatory decision or commercial update was announced.
- ACACIA-HCM CMR sub-study showed statistically significant reductions in LVMI and wall thickness at 36 weeks (p<0.001)
- ACACIA-HCM KCCQ-OSS analysis showed 4.0-point greater improvement vs placebo at Week 36
- FOREST-HCM data: 2.9% of 410 oHCM patients had LVEF <50%, none <40%, no heart failure hospitalizations or deaths
- Company plans to submit sNDA for aficamten in nHCM in Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access